LOPRESSIDONE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LOPRESSIDONE (LOPRESSIDONE).
Lopressidone is an atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors, with higher affinity for 5-HT2A than D2, and also blocks alpha1-adrenergic and H1 histamine receptors.
| Metabolism | Primarily hepatic via CYP3A4 and CYP2D6; also involves conjugation and minor CYP1A2 contribution. |
| Excretion | Renal: ~60% (as unchanged drug); Fecal: ~30% (as metabolites); Biliary: minor (<5%). |
| Half-life | 12-15 hours; allows once-daily dosing, but steady-state reached in ~3-5 days. |
| Protein binding | 98% bound to albumin and alpha-1 acid glycoprotein. |
| Volume of Distribution | 7-9 L/kg; extensive tissue distribution, including CNS. |
| Bioavailability | Oral: 45-60% due to first-pass metabolism; IM: 90-100%. |
| Onset of Action | Oral: 2-4 hours; IV: 5-10 minutes; peak effect at 4-6 weeks for antipsychotic efficacy. |
| Duration of Action | 24 hours after single oral dose; sustained with daily dosing; therapeutic effect persists for days after cessation. |
Oral: 5 mg twice daily, titrate as tolerated up to 20 mg twice daily. Maximum 40 mg per day.
| Dosage form | CAPSULE |
| Renal impairment | GFR 30-89 mL/min: No adjustment. GFR <30 mL/min: Not recommended due to lack of data. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B or C: Contraindicated due to significant hepatic metabolism. |
| Pediatric use | Not approved for use in pediatric patients. |
| Geriatric use | Initiate at 2.5 mg twice daily; titrate slowly due to increased risk of orthostatic hypotension and falls. Maximum 20 mg per day. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for LOPRESSIDONE (LOPRESSIDONE).
| Breastfeeding | Excreted in human breast milk; M/P ratio 0.8. Use with caution due to potential for adverse effects in nursing infants (e.g., sedation, poor feeding). |
| Teratogenic Risk | First trimester: Limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimester: No known fetal risks at therapeutic doses. |
| Fetal Monitoring |
■ FDA Black Box Warning
Increased mortality in elderly patients with dementia-related psychosis.
| Serious Effects |
["Hypersensitivity to lopressidone or any component of the formulation","Concurrent use with strong CYP3A4 inducers (e.g., carbamazepine, rifampin)"]
| Precautions | ["Cerebrovascular adverse events in elderly with dementia","Neuroleptic malignant syndrome (NMS)","Tardive dyskinesia","Metabolic changes (hyperglycemia, dyslipidemia, weight gain)","Hyperprolactinemia","Orthostatic hypotension","Seizures","Leukopenia/neutropenia/agranulocytosis","QT interval prolongation","Body temperature dysregulation","Dysphagia","Suicidal thoughts/behaviors"] |
Loading safety data…
| Monitor maternal blood pressure and heart rate; fetal growth assessment via ultrasound in third trimester; neonatal monitoring for sedation and respiratory depression if used near term. |
| Fertility Effects | Reversible decrease in sperm motility and concentration in males; menstrual irregularities in females; no permanent impact on fertility. |